alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Pharmacotherapy for Vascular Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS drugs 2017-09 Treatments

    Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer's disease (AD).

  2. Metformin and Alzheimer's disease, dementia and cognitive impairment: a systematic review protocol

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. JBI database of systematic reviews and implementation reports 2017-08 Drug development

    The objective of the review is to assess the effect of metformin on the risk, progression and severity of Alzheimer's disease and other forms of dementia, as well as any measures of cognitive performance or impairment.

  3. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Expert opinion on drug safety 2017-07-12 Treatments

    The prevalence of Alzheimer's disease (AD) continues to rise, while treatment options for cognitive impairment are limited.

  4. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Oxidative medicine and cellular longevity 2017-07-09 Drug development

    The results of epidemiological and pathophysiological studies suggest that type 2 diabetes mellitus (T2DM) may predispose to Alzheimer's disease (AD).

  5. Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of molecular graphics & modelling 2017-06-29 Treatments

    In this report we assessed by docking and molecular dynamics the binding mechanisms of three FDA-approved Alzheimer drugs, inhibitors of the enzyme acetylcholinesterase (AChE): donepezil, galantamine and rivastigmine.

  6. Anti-tau vaccine is successful in clinical trial for people with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Nursing older people 2017-05-31 Drug development

    Alzheimer's disease progressively impairs cognition and daily function, and death usually occurs five to ten years after diagnosis.

  7. Omega-3 Use in Psychiatry: Evidence-Based or Elegance-Based?

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of dietary supplements 2017-05-30 Prevention and risk

    Use of omega-3 in psychiatric practice is on the rise.

  8. Circadian Disruption Associated with Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current neurology and neuroscience reports 2017-04 Risk factors

    Alzheimer's disease (AD) is increasing in prevalence and has a significant impact on caregivers and the healthcare system.

  9. Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS & neurological disorders drug targets 2017 Treatments

    The major pharmacokinetic interactions identified concerned fluoxetine, paroxetine and ketoconazole when used with galantamine or donepezil.

  10. Pioglitazone for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Expert opinion on investigational drugs 2016-12-04 Clinical trials

    Alzheimer's disease (AD) is the most common cause of dementia in the elderly.

  11. Medicare and Amyloid PET Imaging: The Battle Over Evidence

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of aging & social policy 2016-06-10 Brain scans and imaging

    We examine a recent dispute regarding the Centers for Medicare and Medicaid Services' (CMS) refusal to unconditionally pay for amyloid positron emission tomography (PET) imaging for Medicare beneficiaries being assessed for Alzheimer's disease.

  12. Unmet needs in Parkinson disease: Motor and non-motor

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Parkinsonism & related disorders 2020-11-01 End-of-life care

    Compared to other neurodegenerative diseases, Parkinson's disease (PD) is distinctive in terms of marked symptomatic variability and prognosis, as well as for the wide variety of symptomatic treatment options.

  13. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biochemical pharmacology 2020-04-02 Risk factors

    Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly failed in clinical trials.

  14. The Future of Anti-Amyloid Trials

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The journal of prevention of Alzheimer's disease 2020-01-01 Treatments

    The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise.

  15. Current and Future Treatments in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Seminars in neurology 2019-03-29 Treatments

    The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and nonpharmacological management and care planning predicated on patient-centered psychoeducation, shared goal-setting, and decision-making forged by a strong triadic relationship between clinician and the patient-caregiver dyad.

  16. Medical Use of Cannabinoids

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Drugs 2018-11-01 Brain scans and imaging

    As a result, it has been reported that changes in endocannabinoid levels may be related to neurological diseases such as Parkinson's disease, Huntington's disease, Alzheimer's disease and multiple sclerosis, as well as anorexia and irritable bowel syndrome.

  17. Drug development for Alzheimer's disease: review

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of drug targeting 2018-06-20 Drug development

    Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as one of the most intractable medical problems with heavy social and economic costs.

  18. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of controlled release : official journal of the Controlled Release Society 2018-05-24 Treatments

    However, there is also some limitation associated with IN like poor drug permeation through the nasal mucosa and mucociliary clearance.

  19. Therapeutic role of rifampicin in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Psychiatry and clinical neurosciences 2018-02-10 Drug development

    Rifampicin exerts significant brain protective functions in multiple experimental models.

  20. Trends in GPCR drug discovery: new agents, targets and indications

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Drug discovery 2017-10-27 Risk factors

    G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability.

  21. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of medicinal chemistry 2017-08-08 Treatments

    The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule and biological drug candidates.

  22. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biotechnology advances 2016-12-30 Drug development

    Alzheimer's disease (AD) is a severe, chronic and progressive neurodegenerative disease associated with memory and cognition impairment ultimately leading to death.

  23. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. PloS one 2016-12-22 Drug development

    Traditional drug development for Alzheimer's disease (AD) is costly, time consuming and burdened by a very low success rate.

  24. [Significance and progress of DIAN/A4/API]

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nihon rinsho. Japanese journal of clinical medicine 2016-03 Risk genes beyond APOE

    The DIAN observational study compared the pathophysiological markers between mutation carriers and non-carriers for autosomal dominant Alzheimer's disease.

  25. Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecules (Basel, Switzerland) 2016-01-11 Treatments

    Dugesia tigrina is a non-parasitic platyhelminth, which has been recently utilized in pharmacological models, regarding the nervous system, as it presents a wide sensitivity to drugs.

From across this topic

10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics